BackRapid Dose Therapeutics Overview

Rapid Dose Therapeutics Common Stock

Rapid Dose Therapeutics's common stock is $30M.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$29.56M
↑ 2.21% YoYΔ $638475.00 vs prior year quarter

Peer trimmed avg / median

Loading

Rapid Dose Therapeutics Common Stock History

Loading

Rapid Dose Therapeutics vs. peers: Common Stock Comparison

Loading

Rapid Dose Therapeutics Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Rapid Dose Therapeutics (RDTCF) FAQ

Rapid Dose Therapeutics's common stock stands at $30M as of August 2026. That compares with $29M in the prior-year period — up 2.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Rapid Dose Therapeutics reported $30M in common stock versus $29M a year earlier — a 2.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $29M in the prior-year period — up 2.2% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Rapid Dose Therapeutics's common stock evolved across reporting periods, while the comparison chart places RDTCF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, common stock is commonly used to spot outliers. Rapid Dose Therapeutics's reading of $30M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.